Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon Assisted DAC Biotechnology's Fourth ADC Drug DXC007 Getting Approved for Clinical Use
Oct 09,2021
Medicilon won the "Science and Innovation Golden Horse Excellent Company Award " at the 2021 Science and Technology Leaders Summit
On July 22, 2019, the Shanghai Sci-Tech Innovation Board (STAR) opened.  Two years later, on July 22, 2021, 313 companies are listed on the STAR. 
More
Medicilon won the "Science and Innovation Golden Horse Excellent Company Award " at the 2021 Science and Technology Leaders Summit
Sep 22,2021
Medicilon is Listed on the Top Chinese R&D CRO Enterprises in 2021
Shanghai Medicilon Inc. (Medicilon) was invited to participate in this event and was awarded the Top Chinese R&D CRO Enterprises in 2021 .
More
Medicilon is Listed on the Top Chinese R&D CRO Enterprises in 2021
Sep 22,2021
Medicilon attended the 21st China International Fair for Investment and Trade
Medicilon attended the 21st China International Fair for Investment and Trade and signed a strategic collaboration agreement with Xiamen Biotime. The 21st China International Fair
More
Medicilon attended the 21st China International Fair for Investment and Trade
Sep 22,2021
Targeting IL-23, Medicilon Assists the Development of a Variety of New Drugs for Psoriasis
IL-23 is mainly produced by activated dendritic cells, macrophages and monocytes. It is a new member of the IL-12 heterodimeric cytokine family.
More
Targeting IL-23, Medicilon Assists the Development of a Variety of New Drugs for Psoriasis
Sep 15,2021
The 19th Annual San Diego BioPharma Conference
Agenda 9:00 am Welcome and Opening Remarks Tao Wu, PhD, President, SABPA Yi Liu, PhD, Chair, BioPharmaCommittee, SABPA; CEO, Kumqat Biosciences 9:15 am Floyd Romesberg,
More
The 19th Annual San Diego BioPharma Conference
Sep 13,2021
Medicilon won the "Science and Technology Innovation Service Demonstration Case" Award
Shanghai Medicilon Inc. (Medicilon) "Internet + One-Stop Preclinical R&D Service Platform" was awarded the "Science and Technology Innovation Service Demonstration Case” award.
More
Medicilon won the "Science and Technology Innovation Service Demonstration Case" Award
Sep 13,2021
Medicilon appoints Dr. Hong Wan as Vice President of DMPK and Bioanalysis Department
Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Hong Wan as Vice President of DMPK and Bioanalysis Department. Dr. Hong
More
Medicilon appoints Dr. Hong Wan as Vice President of DMPK and Bioanalysis Department
Aug 16,2021
Kumquat Biosciences and Eli Lilly have reached a partnership to jointly develop tumor immune small molecule drugs
Recently, Loxo Oncology, a research and development group of Eli Lilly, and Kumquat Biosciences (Kumquat) announced that the two parties have reached an exclusive collaboration
More
Kumquat Biosciences and Eli Lilly have reached a partnership to jointly develop tumor immune small molecule drugs
Aug 16,2021
Qing Ruan, Deputy Director of Shanghai Municipal Development and Reform Commission, and his team examined Medicilon
On August 4, 2021, Mr. Qing Ruan, Deputy Director of Shanghai Municipal Development and Reform Commission, and his team visited Shanghai Medicilon Inc. (Medicilon) at
More
Qing Ruan, Deputy Director of Shanghai Municipal Development and Reform Commission, and his team examined Medicilon
Aug 13,2021
Medicilon assists Ringene Biopharma 's SHP2 allosteric inhibitor RG001 tablet to be approved for clinical use
Recently, Shanghai Ringene Biopharma (Ringene) announced that the company's self-developed anti-tumor class I new drug SHP2 allosteric inhibitor RG001 tablet has been approved for clinical
More
Medicilon assists Ringene Biopharma 's SHP2 allosteric inhibitor RG001 tablet to be approved for clinical use
Aug 06,2021
Medicilon assists Leado Pharma to obtain clinical approval for small molecule inhibitor LDS tablets targeting transient receptor potential channels
On July 28, 2021, the Class 1 innovative drug LDS tablets developed by Shanghai Leado Pharma Technology Co., Ltd. (Leado Pharma) received the National Medical
More
Medicilon assists Leado Pharma to obtain clinical approval for small molecule inhibitor LDS tablets targeting transient receptor potential channels
Jun 25,2021
Medicilon's "New Drugs + AI Innov Forum" was successful held
When AI accurately predicts the "difficult” protein 3D structure; When AI completes the new drug design within 21 days; When AI discovers a new mechanism
More
Medicilon's "New Drugs + AI Innov Forum" was successful held